Payment overview · 2025
General Payments
$279.90
18 reported records · 9 companies
Healthcare provider profile · identity verified
Benjamin Dwight Mills, DO
Allopathic & Osteopathic Physicians|Internal Medicine · JONESBORO, AR · NPI 1477119543
Verified facts
What the public records show
CMS Open Payments records show Benjamin Dwight Mills, DO received $279.90 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 56.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $156.99 | 56.1% | 10 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $20.18 | 7.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $18.41 | 6.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.64 | 5.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.43 | 5.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.17 | 5.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.26 | 5.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.99 | 5.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.83 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.90 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $139.81 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.86 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $10.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 726 | 195 |
| Alprazolam | Alprazolam | 565 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 560 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 504 | 138 |
| Omeprazole | Omeprazole | 490 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 454 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 404 | 108 |
| Gabapentin | Gabapentin | 403 | 100 |
| Duloxetine Hcl | Duloxetine Hcl | 380 | 105 |
| Losartan Potassium | Losartan Potassium | 329 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 73 |
| Trazodone Hcl | Trazodone Hcl | 295 | 71 |
| Metformin Hcl | Metformin Hcl | 285 | 80 |
| Lisinopril | Lisinopril | 284 | 74 |
| Potassium Chloride | Potassium Chloride | 284 | 77 |
| Furosemide | Furosemide | 268 | 80 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 234 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 213 | 85 |
| Eliquis | Apixaban | 209 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 53 |
| Meloxicam | Meloxicam | 178 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 49 |
| Tramadol Hcl | Tramadol Hcl | 168 | 48 |
| Clonazepam | Clonazepam | 164 | 30 |
| Montelukast Sodium | Montelukast Sodium | 160 | 36 |
| Spironolactone | Spironolactone | 160 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 39 |
| Simvastatin | Simvastatin | 153 | 39 |
| Ozempic | Semaglutide | 149 | 32 |
| Lorazepam | Lorazepam | 141 | 34 |
| Donepezil Hcl | Donepezil Hcl | 136 | 26 |
| Carvedilol | Carvedilol | 134 | 41 |
| Mounjaro | Tirzepatide | 131 | 23 |
| Sertraline Hcl | Sertraline Hcl | 130 | 27 |
| Jardiance | Empagliflozin | 129 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 127 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 114 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 39 |
| Celecoxib | Celecoxib | 104 | 33 |
| Allopurinol | Allopurinol | 97 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 27 |
| Famotidine | Famotidine | 92 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 18 |
| Ondansetron Odt | Ondansetron | 85 | 30 |
| Buspirone Hcl | Buspirone Hcl | 84 | 19 |
| Bupropion Xl | Bupropion Hcl | 80 | 21 |
| Metformin Hcl Er | Metformin Hcl | 80 | 26 |
| Atenolol | Atenolol | 77 | 21 |
| Ezetimibe | Ezetimibe | 77 | 21 |
| Pregabalin | Pregabalin | 76 | 21 |
| Glipizide | Glipizide | 72 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 17 |
| Mirtazapine | Mirtazapine | 68 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 15 |
| Memantine Hcl | Memantine Hcl | 66 | 11 |
| Nitroglycerin | Nitroglycerin | 65 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 26 |
| Trulicity | Dulaglutide | 63 | 15 |
| Alendronate Sodium | Alendronate Sodium | 62 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 14 |
| Estradiol | Estradiol | 56 | 15 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 55 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 16 |
| Finasteride | Finasteride | 55 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Diazepam | Diazepam | 50 | suppressed |
| Cefdinir | Cefdinir | 47 | 38 |
| Temazepam | Temazepam | 46 | 11 |
| Prednisone | Prednisone | 45 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 13 |
| Synthroid | Levothyroxine Sodium | 44 | 11 |
| Methocarbamol | Methocarbamol | 43 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 43 | suppressed |
| Sotalol | Sotalol Hcl | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 14 |
| Topiramate | Topiramate | 41 | 11 |
| Glimepiride | Glimepiride | 40 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 14 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 13 |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 14 |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | 11 |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.90 · 18 records | ABBVIE INC. | Arikayce, CAPVAXIVE, GARDASIL 9, GEMTESA, JARDIANCE, LifeVest, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error